Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Retained Earnings came in at -$430.0 million in Q1 2026, down 191845.54% YoY from N/an in Q1 2025, and down 3.14% on a QoQ basis from -$416.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Retained Earnings data on file, last reported at -$430.0 million in Q1 2026.
- Quarterly Retained Earnings fell 191845.54% year-over-year to -$430.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$430.0 million (down 191845.54% YoY) and the FY2025 annual result came in at -$339000.0, down 212.25% from the prior year.
- Retained Earnings retreated to -$430.0 million in Q1 2026, from -$416.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $302000.0 in Q3 2024 to a low of -$430.0 million in Q1 2026.
- A 5-year average of -$106.2 million and a median of -$3.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 125.72% — and 2025, when it sank 1437372.41%.
- Tracing ENTA's Retained Earnings over 5 years: stood at -$2.7 million in 2022, then tumbled by 8886.99% to -$240.4 million in 2023, then surged by 99.99% to -$29000.0 in 2024, then slumped by 1437372.41% to -$416.9 million in 2025, then fell by 3.14% to -$430.0 million in 2026.
- The last three Retained Earnings figures came in at -$430.0 million (Q1 2026), -$416.9 million (Q4 2025), and -$339000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -449.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -449.46 Mn |
| Mar 31, 2026 | -429.96 Mn |
| Dec 31, 2025 | -416.87 Mn |
| Sep 30, 2025 | -339,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | -224,000.00 |
| Dec 31, 2024 | -29,000.00 |
| Sep 30, 2024 | 302,000.00 |
| Jun 30, 2024 | -653,000.00 |
| Mar 31, 2024 | -271.56 Mn |
| Dec 31, 2023 | -240.40 Mn |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -178.89 Mn |
| Mar 31, 2023 | -139.82 Mn |
| Dec 31, 2022 | -2.68 Mn |
| Sep 30, 2022 | -73.18 Mn |
| Jun 30, 2022 | -46.83 Mn |
| Mar 31, 2022 | -3.04 Mn |
| Dec 31, 2021 | -1.01 Mn |
| Sep 30, 2021 | 48.58 Mn |